Endomyocardial and pericardial aspergillosis in critically ill patients
Summary Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection affecting mainly immunocompromised hosts; however, during the last two decades its incidence was increasingly observed in critically ill immunocompetent patients. The objective of this study is to descri...
Gespeichert in:
Veröffentlicht in: | Mycoses 2017-09, Vol.60 (9), p.576-580 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 580 |
---|---|
container_issue | 9 |
container_start_page | 576 |
container_title | Mycoses |
container_volume | 60 |
creator | Dimopoulos, George Frantzeskaki, Frantzeska Kosmopoulos, Marinos Taccone, Fabio Sylvio Van den Abeele, Anne‐Marie Bulpa, Pierre Forêt, Frederic Vogelaers, Dirk Blot, Stijn Blasco‐Navalpotro, Miguel Brusselaers, Nele Cardoso, Teresa Charles, Pierre‐Emmanuel Clause, Didier Courouble, Patricia Laere, Emmanuel Li, Dan Martin, Claude Mashayekhi, Shahram Meersseman, Wouter Misset, Benoit Paiva, José Artur Pasqualotto, Alessandro Pérez, Marcos Rao, Ratna Rello, Jordi Souto, Jessica Spapen, Herbert Vandewoude, Koenraad |
description | Summary
Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection affecting mainly immunocompromised hosts; however, during the last two decades its incidence was increasingly observed in critically ill immunocompetent patients. The objective of this study is to describe the clinical characteristics of histologically proven endomyocardial and pericardial invasion, in the context of IA, in critically ill patients. Eight critically ill patients with histopathological confirmation of endomyocardial/pericardial aspergillosis were evaluated. Risk factors, clinical and laboratory characteristics, treatment, histopathological characteristics and mortality were recorded. Signs and symptoms of cardiac dysfunction were not observed in any of the patients. Therapy was administered to six of them shortly after the first positive culture. The observed histopathological lesions included haemorrhagic lesions, small vessels with central thrombosis and surrounding consolidated tissue with necrosis. Voriconazole, caspofungin, lipid amphotericin B and itraconazole were the used antifungals. The mortality rate was high (87.5%). Endomyocardial and pericardial aspergillosis are devastating complications of invasive aspergillosis. Clinical suspicion is low making the diagnosis difficult, therefore histopathological examination of tissues are required. The mortality is high. |
doi_str_mv | 10.1111/myc.12630 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_496857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1899117191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3910-636c4f0a4ac268a432917fae997b8b434241c103d89da3c2fbb6b3612a3ac2643</originalsourceid><addsrcrecordid>eNp1kctOxCAUhonR6HhZ-AKmiRtd1OEAQlmaiY4mGje6cEUopQalF2Ea07cX7TgLE8_mXPj4w-FH6BjwBaSYN6O5AMIp3kIzYFTm-BKLbTTDktJcMCz20H6MbxiDkITvoj1SMCk4gRlaXrdV14yd0aFy2me6rbLeBrfpY-penfdddDFzbWaCW6VT78csTbNer5xtV_EQ7dTaR3u0zgfo-eb6aXGb3z8u7xZX97mhEnDOKTesxpppQ3ihGSUSRK2tlKIsSkYZYWAA06qQlaaG1GXJS8qBaPp9g9EDlE-68dP2Q6n64BodRtVpp9aj91RZxSQvLkXizya-D93HYONKNS4a671ubTdEBYWUAAIkJPT0D_rWDaFN2yiQFBeYS0kSdT5RJnQxBltvngBYfbuhkhvqx43EnqwVh7Kx1Yb8_f4EzCfg03k7_q-kHl4Wk-QXdqKTbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1930806992</pqid></control><display><type>article</type><title>Endomyocardial and pericardial aspergillosis in critically ill patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dimopoulos, George ; Frantzeskaki, Frantzeska ; Kosmopoulos, Marinos ; Taccone, Fabio Sylvio ; Van den Abeele, Anne‐Marie ; Bulpa, Pierre ; Forêt, Frederic ; Vogelaers, Dirk ; Blot, Stijn ; Blasco‐Navalpotro, Miguel ; Brusselaers, Nele ; Cardoso, Teresa ; Charles, Pierre‐Emmanuel ; Clause, Didier ; Courouble, Patricia ; Laere, Emmanuel ; Li, Dan ; Martin, Claude ; Mashayekhi, Shahram ; Meersseman, Wouter ; Misset, Benoit ; Paiva, José Artur ; Pasqualotto, Alessandro ; Pérez, Marcos ; Rao, Ratna ; Rello, Jordi ; Souto, Jessica ; Spapen, Herbert ; Vandewoude, Koenraad</creator><creatorcontrib>Dimopoulos, George ; Frantzeskaki, Frantzeska ; Kosmopoulos, Marinos ; Taccone, Fabio Sylvio ; Van den Abeele, Anne‐Marie ; Bulpa, Pierre ; Forêt, Frederic ; Vogelaers, Dirk ; Blot, Stijn ; Blasco‐Navalpotro, Miguel ; Brusselaers, Nele ; Cardoso, Teresa ; Charles, Pierre‐Emmanuel ; Clause, Didier ; Courouble, Patricia ; Laere, Emmanuel ; Li, Dan ; Martin, Claude ; Mashayekhi, Shahram ; Meersseman, Wouter ; Misset, Benoit ; Paiva, José Artur ; Pasqualotto, Alessandro ; Pérez, Marcos ; Rao, Ratna ; Rello, Jordi ; Souto, Jessica ; Spapen, Herbert ; Vandewoude, Koenraad ; AspICU investigators</creatorcontrib><description>Summary
Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection affecting mainly immunocompromised hosts; however, during the last two decades its incidence was increasingly observed in critically ill immunocompetent patients. The objective of this study is to describe the clinical characteristics of histologically proven endomyocardial and pericardial invasion, in the context of IA, in critically ill patients. Eight critically ill patients with histopathological confirmation of endomyocardial/pericardial aspergillosis were evaluated. Risk factors, clinical and laboratory characteristics, treatment, histopathological characteristics and mortality were recorded. Signs and symptoms of cardiac dysfunction were not observed in any of the patients. Therapy was administered to six of them shortly after the first positive culture. The observed histopathological lesions included haemorrhagic lesions, small vessels with central thrombosis and surrounding consolidated tissue with necrosis. Voriconazole, caspofungin, lipid amphotericin B and itraconazole were the used antifungals. The mortality rate was high (87.5%). Endomyocardial and pericardial aspergillosis are devastating complications of invasive aspergillosis. Clinical suspicion is low making the diagnosis difficult, therefore histopathological examination of tissues are required. The mortality is high.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/myc.12630</identifier><identifier>PMID: 28497621</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Amphotericin B ; Amphotericin B - therapeutic use ; Antifungal Agents - therapeutic use ; Aspergillosis ; Caspofungin ; Critical Illness ; critically ill ; Echinocandins - therapeutic use ; endomyocardium ; Female ; Heart diseases ; Heart Diseases - drug therapy ; Heart Diseases - epidemiology ; Heart Diseases - microbiology ; Humans ; Immunocompetence ; Immunocompromised Host ; Immunocompromised hosts ; Incidence ; Invasive Fungal Infections - drug therapy ; Invasive Fungal Infections - epidemiology ; Invasive Fungal Infections - microbiology ; Itraconazole ; Lipopeptides - therapeutic use ; Male ; Middle Aged ; Mortality ; Myocardium - pathology ; pericardium ; Pericardium - microbiology ; Risk Factors ; Thrombosis ; Voriconazole ; Voriconazole - therapeutic use</subject><ispartof>Mycoses, 2017-09, Vol.60 (9), p.576-580</ispartof><rights>2017 Blackwell Verlag GmbH</rights><rights>2017 Blackwell Verlag GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3910-636c4f0a4ac268a432917fae997b8b434241c103d89da3c2fbb6b3612a3ac2643</citedby><cites>FETCH-LOGICAL-c3910-636c4f0a4ac268a432917fae997b8b434241c103d89da3c2fbb6b3612a3ac2643</cites><orcidid>0000-0002-3897-6282</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fmyc.12630$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fmyc.12630$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28497621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136595945$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Dimopoulos, George</creatorcontrib><creatorcontrib>Frantzeskaki, Frantzeska</creatorcontrib><creatorcontrib>Kosmopoulos, Marinos</creatorcontrib><creatorcontrib>Taccone, Fabio Sylvio</creatorcontrib><creatorcontrib>Van den Abeele, Anne‐Marie</creatorcontrib><creatorcontrib>Bulpa, Pierre</creatorcontrib><creatorcontrib>Forêt, Frederic</creatorcontrib><creatorcontrib>Vogelaers, Dirk</creatorcontrib><creatorcontrib>Blot, Stijn</creatorcontrib><creatorcontrib>Blasco‐Navalpotro, Miguel</creatorcontrib><creatorcontrib>Brusselaers, Nele</creatorcontrib><creatorcontrib>Cardoso, Teresa</creatorcontrib><creatorcontrib>Charles, Pierre‐Emmanuel</creatorcontrib><creatorcontrib>Clause, Didier</creatorcontrib><creatorcontrib>Courouble, Patricia</creatorcontrib><creatorcontrib>Laere, Emmanuel</creatorcontrib><creatorcontrib>Li, Dan</creatorcontrib><creatorcontrib>Martin, Claude</creatorcontrib><creatorcontrib>Mashayekhi, Shahram</creatorcontrib><creatorcontrib>Meersseman, Wouter</creatorcontrib><creatorcontrib>Misset, Benoit</creatorcontrib><creatorcontrib>Paiva, José Artur</creatorcontrib><creatorcontrib>Pasqualotto, Alessandro</creatorcontrib><creatorcontrib>Pérez, Marcos</creatorcontrib><creatorcontrib>Rao, Ratna</creatorcontrib><creatorcontrib>Rello, Jordi</creatorcontrib><creatorcontrib>Souto, Jessica</creatorcontrib><creatorcontrib>Spapen, Herbert</creatorcontrib><creatorcontrib>Vandewoude, Koenraad</creatorcontrib><creatorcontrib>AspICU investigators</creatorcontrib><title>Endomyocardial and pericardial aspergillosis in critically ill patients</title><title>Mycoses</title><addtitle>Mycoses</addtitle><description>Summary
Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection affecting mainly immunocompromised hosts; however, during the last two decades its incidence was increasingly observed in critically ill immunocompetent patients. The objective of this study is to describe the clinical characteristics of histologically proven endomyocardial and pericardial invasion, in the context of IA, in critically ill patients. Eight critically ill patients with histopathological confirmation of endomyocardial/pericardial aspergillosis were evaluated. Risk factors, clinical and laboratory characteristics, treatment, histopathological characteristics and mortality were recorded. Signs and symptoms of cardiac dysfunction were not observed in any of the patients. Therapy was administered to six of them shortly after the first positive culture. The observed histopathological lesions included haemorrhagic lesions, small vessels with central thrombosis and surrounding consolidated tissue with necrosis. Voriconazole, caspofungin, lipid amphotericin B and itraconazole were the used antifungals. The mortality rate was high (87.5%). Endomyocardial and pericardial aspergillosis are devastating complications of invasive aspergillosis. Clinical suspicion is low making the diagnosis difficult, therefore histopathological examination of tissues are required. The mortality is high.</description><subject>Amphotericin B</subject><subject>Amphotericin B - therapeutic use</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Aspergillosis</subject><subject>Caspofungin</subject><subject>Critical Illness</subject><subject>critically ill</subject><subject>Echinocandins - therapeutic use</subject><subject>endomyocardium</subject><subject>Female</subject><subject>Heart diseases</subject><subject>Heart Diseases - drug therapy</subject><subject>Heart Diseases - epidemiology</subject><subject>Heart Diseases - microbiology</subject><subject>Humans</subject><subject>Immunocompetence</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>Incidence</subject><subject>Invasive Fungal Infections - drug therapy</subject><subject>Invasive Fungal Infections - epidemiology</subject><subject>Invasive Fungal Infections - microbiology</subject><subject>Itraconazole</subject><subject>Lipopeptides - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardium - pathology</subject><subject>pericardium</subject><subject>Pericardium - microbiology</subject><subject>Risk Factors</subject><subject>Thrombosis</subject><subject>Voriconazole</subject><subject>Voriconazole - therapeutic use</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOxCAUhonR6HhZ-AKmiRtd1OEAQlmaiY4mGje6cEUopQalF2Ea07cX7TgLE8_mXPj4w-FH6BjwBaSYN6O5AMIp3kIzYFTm-BKLbTTDktJcMCz20H6MbxiDkITvoj1SMCk4gRlaXrdV14yd0aFy2me6rbLeBrfpY-penfdddDFzbWaCW6VT78csTbNer5xtV_EQ7dTaR3u0zgfo-eb6aXGb3z8u7xZX97mhEnDOKTesxpppQ3ihGSUSRK2tlKIsSkYZYWAA06qQlaaG1GXJS8qBaPp9g9EDlE-68dP2Q6n64BodRtVpp9aj91RZxSQvLkXizya-D93HYONKNS4a671ubTdEBYWUAAIkJPT0D_rWDaFN2yiQFBeYS0kSdT5RJnQxBltvngBYfbuhkhvqx43EnqwVh7Kx1Yb8_f4EzCfg03k7_q-kHl4Wk-QXdqKTbg</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Dimopoulos, George</creator><creator>Frantzeskaki, Frantzeska</creator><creator>Kosmopoulos, Marinos</creator><creator>Taccone, Fabio Sylvio</creator><creator>Van den Abeele, Anne‐Marie</creator><creator>Bulpa, Pierre</creator><creator>Forêt, Frederic</creator><creator>Vogelaers, Dirk</creator><creator>Blot, Stijn</creator><creator>Blasco‐Navalpotro, Miguel</creator><creator>Brusselaers, Nele</creator><creator>Cardoso, Teresa</creator><creator>Charles, Pierre‐Emmanuel</creator><creator>Clause, Didier</creator><creator>Courouble, Patricia</creator><creator>Laere, Emmanuel</creator><creator>Li, Dan</creator><creator>Martin, Claude</creator><creator>Mashayekhi, Shahram</creator><creator>Meersseman, Wouter</creator><creator>Misset, Benoit</creator><creator>Paiva, José Artur</creator><creator>Pasqualotto, Alessandro</creator><creator>Pérez, Marcos</creator><creator>Rao, Ratna</creator><creator>Rello, Jordi</creator><creator>Souto, Jessica</creator><creator>Spapen, Herbert</creator><creator>Vandewoude, Koenraad</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0002-3897-6282</orcidid></search><sort><creationdate>201709</creationdate><title>Endomyocardial and pericardial aspergillosis in critically ill patients</title><author>Dimopoulos, George ; Frantzeskaki, Frantzeska ; Kosmopoulos, Marinos ; Taccone, Fabio Sylvio ; Van den Abeele, Anne‐Marie ; Bulpa, Pierre ; Forêt, Frederic ; Vogelaers, Dirk ; Blot, Stijn ; Blasco‐Navalpotro, Miguel ; Brusselaers, Nele ; Cardoso, Teresa ; Charles, Pierre‐Emmanuel ; Clause, Didier ; Courouble, Patricia ; Laere, Emmanuel ; Li, Dan ; Martin, Claude ; Mashayekhi, Shahram ; Meersseman, Wouter ; Misset, Benoit ; Paiva, José Artur ; Pasqualotto, Alessandro ; Pérez, Marcos ; Rao, Ratna ; Rello, Jordi ; Souto, Jessica ; Spapen, Herbert ; Vandewoude, Koenraad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3910-636c4f0a4ac268a432917fae997b8b434241c103d89da3c2fbb6b3612a3ac2643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Amphotericin B</topic><topic>Amphotericin B - therapeutic use</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Aspergillosis</topic><topic>Caspofungin</topic><topic>Critical Illness</topic><topic>critically ill</topic><topic>Echinocandins - therapeutic use</topic><topic>endomyocardium</topic><topic>Female</topic><topic>Heart diseases</topic><topic>Heart Diseases - drug therapy</topic><topic>Heart Diseases - epidemiology</topic><topic>Heart Diseases - microbiology</topic><topic>Humans</topic><topic>Immunocompetence</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>Incidence</topic><topic>Invasive Fungal Infections - drug therapy</topic><topic>Invasive Fungal Infections - epidemiology</topic><topic>Invasive Fungal Infections - microbiology</topic><topic>Itraconazole</topic><topic>Lipopeptides - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardium - pathology</topic><topic>pericardium</topic><topic>Pericardium - microbiology</topic><topic>Risk Factors</topic><topic>Thrombosis</topic><topic>Voriconazole</topic><topic>Voriconazole - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dimopoulos, George</creatorcontrib><creatorcontrib>Frantzeskaki, Frantzeska</creatorcontrib><creatorcontrib>Kosmopoulos, Marinos</creatorcontrib><creatorcontrib>Taccone, Fabio Sylvio</creatorcontrib><creatorcontrib>Van den Abeele, Anne‐Marie</creatorcontrib><creatorcontrib>Bulpa, Pierre</creatorcontrib><creatorcontrib>Forêt, Frederic</creatorcontrib><creatorcontrib>Vogelaers, Dirk</creatorcontrib><creatorcontrib>Blot, Stijn</creatorcontrib><creatorcontrib>Blasco‐Navalpotro, Miguel</creatorcontrib><creatorcontrib>Brusselaers, Nele</creatorcontrib><creatorcontrib>Cardoso, Teresa</creatorcontrib><creatorcontrib>Charles, Pierre‐Emmanuel</creatorcontrib><creatorcontrib>Clause, Didier</creatorcontrib><creatorcontrib>Courouble, Patricia</creatorcontrib><creatorcontrib>Laere, Emmanuel</creatorcontrib><creatorcontrib>Li, Dan</creatorcontrib><creatorcontrib>Martin, Claude</creatorcontrib><creatorcontrib>Mashayekhi, Shahram</creatorcontrib><creatorcontrib>Meersseman, Wouter</creatorcontrib><creatorcontrib>Misset, Benoit</creatorcontrib><creatorcontrib>Paiva, José Artur</creatorcontrib><creatorcontrib>Pasqualotto, Alessandro</creatorcontrib><creatorcontrib>Pérez, Marcos</creatorcontrib><creatorcontrib>Rao, Ratna</creatorcontrib><creatorcontrib>Rello, Jordi</creatorcontrib><creatorcontrib>Souto, Jessica</creatorcontrib><creatorcontrib>Spapen, Herbert</creatorcontrib><creatorcontrib>Vandewoude, Koenraad</creatorcontrib><creatorcontrib>AspICU investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dimopoulos, George</au><au>Frantzeskaki, Frantzeska</au><au>Kosmopoulos, Marinos</au><au>Taccone, Fabio Sylvio</au><au>Van den Abeele, Anne‐Marie</au><au>Bulpa, Pierre</au><au>Forêt, Frederic</au><au>Vogelaers, Dirk</au><au>Blot, Stijn</au><au>Blasco‐Navalpotro, Miguel</au><au>Brusselaers, Nele</au><au>Cardoso, Teresa</au><au>Charles, Pierre‐Emmanuel</au><au>Clause, Didier</au><au>Courouble, Patricia</au><au>Laere, Emmanuel</au><au>Li, Dan</au><au>Martin, Claude</au><au>Mashayekhi, Shahram</au><au>Meersseman, Wouter</au><au>Misset, Benoit</au><au>Paiva, José Artur</au><au>Pasqualotto, Alessandro</au><au>Pérez, Marcos</au><au>Rao, Ratna</au><au>Rello, Jordi</au><au>Souto, Jessica</au><au>Spapen, Herbert</au><au>Vandewoude, Koenraad</au><aucorp>AspICU investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endomyocardial and pericardial aspergillosis in critically ill patients</atitle><jtitle>Mycoses</jtitle><addtitle>Mycoses</addtitle><date>2017-09</date><risdate>2017</risdate><volume>60</volume><issue>9</issue><spage>576</spage><epage>580</epage><pages>576-580</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>Summary
Invasive aspergillosis(IA) is a potentially lethal complication of Aspergillus infection affecting mainly immunocompromised hosts; however, during the last two decades its incidence was increasingly observed in critically ill immunocompetent patients. The objective of this study is to describe the clinical characteristics of histologically proven endomyocardial and pericardial invasion, in the context of IA, in critically ill patients. Eight critically ill patients with histopathological confirmation of endomyocardial/pericardial aspergillosis were evaluated. Risk factors, clinical and laboratory characteristics, treatment, histopathological characteristics and mortality were recorded. Signs and symptoms of cardiac dysfunction were not observed in any of the patients. Therapy was administered to six of them shortly after the first positive culture. The observed histopathological lesions included haemorrhagic lesions, small vessels with central thrombosis and surrounding consolidated tissue with necrosis. Voriconazole, caspofungin, lipid amphotericin B and itraconazole were the used antifungals. The mortality rate was high (87.5%). Endomyocardial and pericardial aspergillosis are devastating complications of invasive aspergillosis. Clinical suspicion is low making the diagnosis difficult, therefore histopathological examination of tissues are required. The mortality is high.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28497621</pmid><doi>10.1111/myc.12630</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-3897-6282</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0933-7407 |
ispartof | Mycoses, 2017-09, Vol.60 (9), p.576-580 |
issn | 0933-7407 1439-0507 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_496857 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Amphotericin B Amphotericin B - therapeutic use Antifungal Agents - therapeutic use Aspergillosis Caspofungin Critical Illness critically ill Echinocandins - therapeutic use endomyocardium Female Heart diseases Heart Diseases - drug therapy Heart Diseases - epidemiology Heart Diseases - microbiology Humans Immunocompetence Immunocompromised Host Immunocompromised hosts Incidence Invasive Fungal Infections - drug therapy Invasive Fungal Infections - epidemiology Invasive Fungal Infections - microbiology Itraconazole Lipopeptides - therapeutic use Male Middle Aged Mortality Myocardium - pathology pericardium Pericardium - microbiology Risk Factors Thrombosis Voriconazole Voriconazole - therapeutic use |
title | Endomyocardial and pericardial aspergillosis in critically ill patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A18%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endomyocardial%20and%20pericardial%20aspergillosis%20in%20critically%20ill%20patients&rft.jtitle=Mycoses&rft.au=Dimopoulos,%20George&rft.aucorp=AspICU%20investigators&rft.date=2017-09&rft.volume=60&rft.issue=9&rft.spage=576&rft.epage=580&rft.pages=576-580&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/myc.12630&rft_dat=%3Cproquest_swepu%3E1899117191%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1930806992&rft_id=info:pmid/28497621&rfr_iscdi=true |